HealthQuill Pharma
The European Commission has approved AbbVie Inc.’s drug for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs.
Drugs Health Pharma

EC approves AbbVie Inc.s drug for a type of juvenile idiopathic arthritis

HQ Team September 22, 2026: The European Commission has approved AbbVie Inc.’s drug for the treatment of active polyarticular juvenile idiopathic arthritis in.

Read More
American pharmaceutical company Johnson & Johnson’s investigational drug met its main goal during end-stage trials for the treatment of manic episodes in adults with bipolar I disorder, according to the company.
Drugs Pharma Research

J&J’s test drug for manic episodes in bipolar disorder meets main goal

HQ Team September 22, 2026: American pharmaceutical company Johnson & Johnson’s investigational drug met its main goal during end-stage trials for the treatment.

Read More
Danish drugmaker Novo Nordisk’s investigational drug, CagriSema, has achieved an estimated average weight loss of 12.4% in diabetic patients during an end-stage trial, better than rival Eli Lilly’s drug.
Health Pharma Research

Novo Nordisk’s test drug outperforms rival Lilly’s in diabetic patients

HQ Team September 21, 2026: Danish drugmaker Novo Nordisk’s investigational drug, CagriSema, has achieved an estimated average weight loss of 12.4% in diabetic.

Read More
The US Food and Drug Administration has approved a combination oral drug from Eli Lilly and Company to treat people with a type of breast cancer that has worsened after at least one hormone treatment.The US Food and Drug Administration has approved a combination oral drug from Eli Lilly and Company to treat people with a type of breast cancer that has worsened after at least one hormone treatment.
Drugs Health Pharma

FDA clears Eli Lilly’s combination drug for metastatic breast cancer

HQ Team September 21, 2026: The US Food and Drug Administration has approved a combination oral drug from Eli Lilly and Company to.

Read More
Australia's Telix Pharmaceuticals will buy ITM Isotope Technologies Munich SE for an upfront payment of $1.65 billion on a cash- and debt-free basis to pocket the Germany-based company’s therapeutic radioisotopic solutions.
Drugs Health Pharma

Australia’s Telix to buy ITM Isotope Technologies for $1.65 billion

HQ Team September 21, 2026: Australia’s Telix Pharmaceuticals will buy ITM Isotope Technologies Munich SE for an upfront payment of $1.65 billion on.

Read More
The death toll from the Ebola virus, which is sweeping through the heart of the Central African region of the Democratic Republic of the Congo (DRC), has neared 3,500 with about 7,000 confirmed cases, the second-largest Ebola outbreak on record.
Drugs Health Pharma

Death toll in Congo’s worst Ebola virus outbreak set to cross 7,000: CDC says

HQ Team September 14, 2026: The death toll from the Ebola virus, which is sweeping through the heart of the Central African region.

Read More
British pharmaceutical company GSK Plc said a new experimental cancer drug helped patients with a difficult-to-treat type of lung cancer live longer than those who received an existing treatment, according to a company statement.
Drugs Medical Pharma

GSK’s test drug cuts death risk by 54% in patients with small lung cancer relapse

HQ Team September 13, 2026:  British pharmaceutical company GSK Plc said a new experimental cancer drug helped patients with a difficult-to-treat type of.

Read More
AstraZeneca’s end-stage trial of an experimental drug to treat breast cancer failed to prolong a patient’s life without the disease progressing or getting worse, according to the Anglo-Swedish company.
Drugs Medical Pharma

AstraZeneca’s test drug for breast cancer fails to prolong life

HQ Team September 13, 2026: AstraZeneca’s end-stage trial of an experimental drug to treat breast cancer failed to prolong a patient’s life without.

Read More
AbbVie Inc.’s experimental drug has reduced the number of migraine days during the menstrual period, meeting a key goal in late-stage trials, the company announced.
Drugs Medical Pharma

AbbVie’s late-stage experimental drug reduces menstrual migraine days

HQ Team September 11, 2026: AbbVie Inc.’s experimental drug has reduced the number of migraine days during the menstrual period, meeting a key.

Read More
A team of neurosurgeons, medical robotics specialists, and advanced energy systems engineers is building  a device that uses high-intensity sound waves to break down targeted diseased tissue without incisions, heat, or trauma, enabling the body to heal itself naturally.
Drugs Medical Pharma

US-based start-up developing medical device to replace surgical incision

HQ Team September 10, 2026: A team of neurosurgeons, medical robotics specialists, and advanced energy systems engineers is building  a device that uses.

Read More